The FDA's recent scrutiny of peptide compounding has sharpened focus on which peptides might offer meaningful rejuvenation signals. Thymalin (a thymic peptide bioregulator) and Cortagen (a tetrapeptide with affinity for nervous and endocrine tissues) represent a stack that targets two systems whose decline drives much of what we call aging. Their mechanisms intersect with pathways like mTOR, autophagy, and NAD+ metabolism, placing them in the same conversation as caloric restriction mimetics. This article discusses peptides as research compounds. It is not medical advice.
Thymalin Restores Thymic Output and T-Cell Repertoire
The thymus involutes early, shrinking functional tissue and reducing naive T-cell production by something like 80-90% by age 50. Thymalin, a complex of peptides extracted from calf thymus, appears to partially reverse this. Research (Khavinson 2003) showed that Thymalin administration in aged animals increased thymic hormone secretion and improved T-cell differentiation markers. The peptide seems to act on thymic epithelial cells, upregulating genes involved in thymopoiesis. This is not simply immune stimulation; it is a restoration of the organ's developmental signaling. In human studies, Thymalin reduced infection rates in elderly cohorts by roughly 30-50% over a year, with effects persisting months after a short course.
One open question is whether Thymalin's effects depend on existing thymic tissue. In very advanced thymic atrophy, the substrate for regeneration may be too scarce. This matters because many people considering thymic peptides are already in their sixth or seventh decade.
Cortagen Modulates the Hypothalamic-Pituitary-Adrenal Axis
Cortagen (a tetrapeptide, Ala-Glu-Asp-Gly) was designed to target nervous tissue, but its effects ripple through endocrine control centers. The hypothalamus governs much of the stress response and circadian hormone release. Cortagen appears to normalize cortisol rhythms and improve neuron survival in the paraventricular nucleus. In animal models of chronic stress, Cortagen reduced corticotropin-releasing hormone overexpression and restored glucocorticoid receptor sensitivity. This is relevant because HPA axis dysfunction is a hallmark of aging, contributing to immune suppression, cognitive decline, and metabolic dysregulation.
When stacked with Thymalin, Cortagen may address the neuroendocrine context that shapes immune function. Thymic output is influenced by glucocorticoids and growth hormone; normalizing these signals could amplify Thymalin's effects. Some researchers have explored this combination in the context of mitochondrial rejuvenation, noting that immune and metabolic aging are intertwined.
NAD+ and Sirtuins as Convergence Points
Both thymic function and HPA axis integrity are energy-dependent. NAD+ levels decline with age, limiting sirtuin activity and impairing cellular repair. Thymalin has been shown to increase activity of SIRT1 in thymocytes, possibly through AMPK activation. Cortagen, meanwhile, may protect hypothalamic neurons from oxidative damage, preserving NAD+ synthesis pathways. This creates a potential synergy with NAD+ precursors or GHK-Cu's epigenetic effects, where sirtuin activation is central.
MOTS-c, a mitochondrial-derived peptide, also enters this picture. It activates AMPK and promotes mitophagy, which could support the energetic demands of thymic regeneration. While not directly part of the Thymalin-Cortagen stack, MOTS-c's mechanism overlaps with the pathways these bioregulators engage. The interplay suggests that immune-endocrine rejuvenation is not isolated; it requires systemic metabolic support.
Autophagy and Protein Homeostasis in Immune Cells
Thymalin's effects on T-cell development may involve autophagy induction. Thymic epithelial cells rely on autophagy to present self-antigens and shape the T-cell repertoire. Age-related decline in autophagy correlates with reduced thymic function. Thymalin upregulates beclin-1 and LC3-II in some models, suggesting it enhances autophagic flux. Cortagen, too, has been linked to improved proteostasis in neurons, possibly through mTORC1 inhibition. This is a common thread with caloric restriction mimetics like rapamycin, though the peptides appear more tissue-specific.
Vesugen, another peptide bioregulator with vascular tropism, could theoretically support thymic blood flow, but its role in this stack is less direct. The focus remains on the thymus-HPA axis connection. GHK-Cu, known for wound healing and epigenetic modulation, might complement by reducing inflammaging, but the core logic of the stack is immune-endocrine recalibration.
Evidence Quality and the FDA Context
The evidence for Thymalin and Cortagen comes largely from Russian research groups, with decades of animal and small human trials. Thymalin has been used in clinical practice in some countries for immunocompromised states, with safety data suggesting low toxicity. Cortagen is less studied but shows consistent neuroprotective effects in models of stroke and cognitive decline. The FDA panel's review has not specifically targeted these peptides, but the broader regulatory uncertainty affects availability. Rigorous, placebo-controlled trials with modern biomarkers are scarce. Most human data rely on infection incidence or subjective well-being, not deep immune phenotyping.
This is general educational content. Personal health decisions should involve a qualified clinician familiar with your medical history. The mechanisms described are plausible and align with current aging biology, but the clinical translation remains tentative. The stack's appeal lies in its multi-target approach: restoring thymic output while normalizing the neuroendocrine environment that governs immunity.